alexa Adjuvant-guidance Of T Cell Responses
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Magdalena Tary-Lehmann
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.020
Abstract
A djuvants are important enhancers of the immune response. The choice of adjuvant is especially crucial in the context of subunit vaccine approaches. In the past, adjuvants have been used with little knowledge of the mechanism by which they exert their effects. Studies on the role of adjuvants on CD4 + T cell responses have shown that different types of adjuvants can polarize the cytokine response while inducing the same proliferative capacity, specificity and avidity of CD4 + T cells. Such responses were shown to be independent of the antigen used and genetic background of the host. Would this also be the case for CD8 + T cells? What is the contribution or importance of providing CD4 + T cell help or toll-like receptor (TLR) ligation in the generation of these CD8 + T cell responses? Studies have shown that CD8 + T cells are guided differently than CD4 + T cells. In addition, it was found that the use of different adjuvants can induce the generation of different CTL populations: cells which kill but do not produce IFN-gamma, cells which do not kill but produce IFN-gamma, and cells which both kill and produce IFN-gamma. By understanding the extent to which one can guide the T cell responses through the use of adjuvants and appropriate CD4 + T cell help or TLR agonists, one can improve both vaccine efficacy and safety. These have broad implications not only for vaccine development, but also in the fields of autoimmunity, transplantation, and tumor biology
Biography
Magdalena Tary-Lehmann is an Adjunct Associate Professor of Case Western Reserve University (CASE) Department of Pathology, Co-Founding Scientist and Chief Scientific Officer for Cellular Technology Limited (CTL). She has published more than 75 papers in peer-reviewed journals. She provides guidance and oversight for technical operations in the GLP laboratory, ensuring the ongoing scientific excellence of CTL. Over the past decade, she has worked with clients and regulatory agencies to develop and validate reference samples and controls for use in regulated immune monitoring assays.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords